200 related articles for article (PubMed ID: 23723317)
1. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial.
Mariette X; Rouanet S; Sibilia J; Combe B; Le Loët X; Tebib J; Jourdan R; Dougados M
Ann Rheum Dis; 2014 Aug; 73(8):1508-14. PubMed ID: 23723317
[TBL] [Abstract][Full Text] [Related]
2. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.
Porter D; van Melckebeke J; Dale J; Messow CM; McConnachie A; Walker A; Munro R; McLaren J; McRorie E; Packham J; Buckley CD; Harvie J; Taylor P; Choy E; Pitzalis C; McInnes IB
Lancet; 2016 Jul; 388(10041):239-47. PubMed ID: 27197690
[TBL] [Abstract][Full Text] [Related]
3. Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis.
Emery P; Mease PJ; Rubbert-Roth A; Curtis JR; Müller-Ladner U; Gaylis NB; Williams S; Reynard M; Tyrrell H
Rheumatology (Oxford); 2011 Dec; 50(12):2223-32. PubMed ID: 21926153
[TBL] [Abstract][Full Text] [Related]
4. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.
Haraoui B; Bokarewa M; Kallmeyer I; Bykerk VP;
J Rheumatol; 2011 Dec; 38(12):2548-56. PubMed ID: 21965646
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure.
Solau-Gervais E; Prudhomme C; Philippe P; Duhamel A; Dupont-Créteur C; Legrand JL; Houvenagel E; Flipo RM
Joint Bone Spine; 2012 May; 79(3):281-4. PubMed ID: 21724444
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)).
Emery P; Deodhar A; Rigby WF; Isaacs JD; Combe B; Racewicz AJ; Latinis K; Abud-Mendoza C; Szczepanski LJ; Roschmann RA; Chen A; Armstrong GK; Douglass W; Tyrrell H
Ann Rheum Dis; 2010 Sep; 69(9):1629-35. PubMed ID: 20488885
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR).
Rubbert-Roth A; Tak PP; Zerbini C; Tremblay JL; Carreño L; Armstrong G; Collinson N; Shaw TM;
Rheumatology (Oxford); 2010 Sep; 49(9):1683-93. PubMed ID: 20463186
[TBL] [Abstract][Full Text] [Related]
10. Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial.
den Broeder AA; Verhoef LM; Fransen J; Thurlings R; van den Bemt BJF; Teerenstra S; Boers N; den Broeder N; van den Hoogen FHJ
Trials; 2017 Aug; 18(1):403. PubMed ID: 28854956
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B;
Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial.
Mease PJ; Cohen S; Gaylis NB; Chubick A; Kaell AT; Greenwald M; Agarwal S; Yin M; Kelman A
J Rheumatol; 2010 May; 37(5):917-27. PubMed ID: 20194448
[TBL] [Abstract][Full Text] [Related]
13. Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial.
Edwards CJ; Östör AJK; Naisbett-Groet B; Kiely P
Rheumatology (Oxford); 2018 Jan; 57(1):84-91. PubMed ID: 29155973
[TBL] [Abstract][Full Text] [Related]
14. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs.
Narvaez J; Díaz-Torné C; Ruiz JM; Hernandez MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
Clin Exp Rheumatol; 2011; 29(6):991-7. PubMed ID: 22133052
[TBL] [Abstract][Full Text] [Related]
15. An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial.
Vital EM; Dass S; Buch MH; Rawstron AC; Emery P
Ann Rheum Dis; 2015 Jun; 74(6):1195-201. PubMed ID: 24443001
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.
Yoo DH; Suh CH; Shim SC; Jeka S; Molina FFC; Hrycaj P; Wiland P; Lee EY; Medina-Rodriguez FG; Shesternya P; Radominski S; Stanislav M; Kovalenko V; Sheen DH; Myasoutova L; Lim MJ; Choe JY; Lee SJ; Lee SY; Kim SH; Park W
BioDrugs; 2017 Aug; 31(4):357-367. PubMed ID: 28612179
[TBL] [Abstract][Full Text] [Related]
17. Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial.
Verhoef LM; den Broeder N; Thurlings RM; van der Laan WH; van der Weele W; Kok MR; Bernelot Moens HJ; Woodworth TG; van den Bemt BJF; van den Hoogen FHJ; den Broeder AA
Lancet Rheumatol; 2019 Nov; 1(3):e145-e153. PubMed ID: 38229391
[TBL] [Abstract][Full Text] [Related]
18. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.
Tak PP; Rigby W; Rubbert-Roth A; Peterfy C; van Vollenhoven RF; Stohl W; Healy E; Hessey E; Reynard M; Shaw T
Ann Rheum Dis; 2012 Mar; 71(3):351-7. PubMed ID: 22012969
[TBL] [Abstract][Full Text] [Related]
19. Swiss consensus statement: Recommendations for optimising re-treatment with MabThera (rituximab) in rheumatoid arthritis.
Dudler J; Finckh A; Kyburz D; Langenegger T; Möller B; Schmiedel U; Walker UA
Swiss Med Wkly; 2010; 140():w13073. PubMed ID: 20648402
[TBL] [Abstract][Full Text] [Related]
20. Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study.
Rigby WF; Mease PJ; Olech E; Ashby M; Tole S
J Rheumatol; 2013 May; 40(5):599-604. PubMed ID: 23547218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
